JP4780817B2 - Epidermis ceramide production promoter and epidermis moisturizing function improving agent containing the same - Google Patents

Epidermis ceramide production promoter and epidermis moisturizing function improving agent containing the same Download PDF

Info

Publication number
JP4780817B2
JP4780817B2 JP2000029319A JP2000029319A JP4780817B2 JP 4780817 B2 JP4780817 B2 JP 4780817B2 JP 2000029319 A JP2000029319 A JP 2000029319A JP 2000029319 A JP2000029319 A JP 2000029319A JP 4780817 B2 JP4780817 B2 JP 4780817B2
Authority
JP
Japan
Prior art keywords
acid
epidermis
ceramide
ceramide production
production promoter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000029319A
Other languages
Japanese (ja)
Other versions
JP2001220345A (en
Inventor
由利 岡野
仁 正木
宏右 鳥居
Original Assignee
株式会社ノエビア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社ノエビア filed Critical 株式会社ノエビア
Priority to JP2000029319A priority Critical patent/JP4780817B2/en
Publication of JP2001220345A publication Critical patent/JP2001220345A/en
Application granted granted Critical
Publication of JP4780817B2 publication Critical patent/JP4780817B2/en
Application status is Expired - Fee Related legal-status Critical
Anticipated expiration legal-status Critical

Links

Description

[0001]
BACKGROUND OF THE INVENTION
TECHNICAL FIELD The present invention relates to an epidermis ceramide production promoter that can promote the production of epidermis ceramide, and an epidermis moisturizing function improving agent that contains this and can enhance the epidermis ceramide and normalize the epidermis moisturizing function.
[0002]
[Prior art]
Ceramide is involved in the protective and moisturizing functions of the epidermis as a constituent of the epidermal intercellular lipid, and the decrease and structure of ceramide due to physical and chemical stresses such as aging, UV exposure, contact with organic solvents and surfactants. As it becomes clear that the above-mentioned function of the epidermis is impaired due to the disturbance of the skin, attempts have been made to compensate for this by external application (Japanese Patent Laid-Open No. 61-260008, 63-192703), and further, the moisture retention function and stability. Many ceramide-like amide derivatives, which are excellent in safety and the like and inexpensive in cost, have been disclosed (Japanese Patent Laid-Open Nos. 63-216812, 63-218609, 63-222107, etc.).
[0003]
However, even if ceramide or a similar compound is applied externally, it is difficult to efficiently transdermally absorb these and use them to reconstruct intercellular lipids in the epidermis. Moreover, originally, it is preferable to activate the production of ceramide in the epidermis, but no effective ceramide production promoter has been reported so far.
[0004]
[Problems to be solved by the invention]
Therefore, an object of the present invention is to obtain an epidermis ceramide production promoter and an epidermis moisturizing function improving agent that can effectively promote the production of ceramide in the epidermis and improve the moisturizing function itself of the epidermis.
[0005]
[Means for Solving the Problems]
In order to solve the above problems, a search for a substance capable of promoting the production of epidermal ceramide was conducted. As a result, one or more selected from the group consisting of fatty acids and salts and derivatives thereof, L-carnitine and DL-carnitine, and It has been found that good results can be obtained by using one or more selected from the group consisting of these salts and derivatives in combination in a carrier or base, and the present invention has been completed.
[0006]
DETAILED DESCRIPTION OF THE INVENTION
The fatty acid that can be used in the present invention is preferably a saturated or unsaturated fatty acid having a straight chain or branched chain having about 6 to 32 carbon atoms. Linear saturated fatty acids include hexanoic acid (caproic acid), octanoic acid (caprylic acid), decanoic acid (capric acid), undecanoic acid, dodecanoic acid (lauric acid), tetradecanoic acid (myristic acid), pentadecanoic acid, hexadecanoic acid (Palmitic acid), octadecanoic acid (stearic acid), eicosanoic acid (arachinic acid), docosanoic acid (behenic acid), etc., as linear monoenoic acid, 9-decenoic acid (caproleic acid), 9-undecenoic acid (9 -Undecylenic acid), 10-Undecenoic acid (10-undecylenic acid), 2-dodecenoic acid (2-laurolenic acid), 5-dodecenoic acid (5-laurolenic acid), 11-dodecenoic acid (11-laurolenic acid), 5 -Tetradecenoic acid (5-myristoleic acid), 9-tetradecenoic acid (9-myristoleic acid), 2-hexadecenoic acid (2-palmitoleic acid), 7-hexadecenoic acid (7- Lumitoleic acid), cis-6-octadecenoic acid (petroceric acid), trans-6-octadecenoic acid (petroceleic acid), cis-9-octadecenoic acid (oleic acid), trans-9-octadecenoic acid (elaidic acid) , Cis-11-eicosenoic acid (gondoic acid), cis-13-docosenoic acid (erucic acid), etc., as dienoic acid, 2,4-hexadienoic acid (sorbic acid), cis-9, cis-12-octa Decadienoic acid (linoleic acid), cis-9, trans-12-octadecadienoic acid (linoleidic acid), etc., as the trienoic acid, cis-9, trans-11, trans-13-octadecatrienoic acid ( α-eleostearic acid), trans-9, trans-11, trans-13-octadecatrienoic acid (β-eleostearic acid), cis-9, cis-12, cis-15-octadecatrienoic acid ( Linolenic acid), trans-9, trans-12, trans-15-octadecatrienoic acid (linoleidic acid), etc. 5,8,11,14-eicosatetraenoic acid (arachidonic acid) and the like. Examples of branched saturated fatty acids include 2-ethylbutanoic acid, 2-methylpentanoic acid, 2-ethylhexanoic acid, 2,2-dimethyloctanoic acid, 14-methylpentadecanoic acid (isopalmitic acid), 16-methyl Examples include heptadecanoic acid (isostearic acid). Further, hydroxy fatty acids such as 12-hydroxystearic acid and natural mixed fatty acids such as coconut oil fatty acid and lanolin fatty acid can be used.
[0007]
Examples of the fatty acid salts include alkali metal salts such as sodium salts and potassium salts, amine salts such as triethanolamine salts, and derivatives such as various esters such as alkyl esters, alkenyl esters, and glyceryl esters of the above fatty acids, and Amides are mentioned. In the present invention, one or more of these fatty acids and salts and derivatives thereof are selected and used. In the epidermis ceramide production promoter according to the present invention, it is appropriate to contain it in a carrier or the like in an amount of about 0.0001 to 5.0% by weight.
[0008]
Next, carnitine used in combination with one or more of the above fatty acids in the present invention is 4-trimethylamino-3-hydroxybutyric acid, which is a known substance. The formulation of carnitine and its salts and derivatives into skin cosmetics has already been disclosed (Japanese Patent Laid-Open No. 51-14802), and it is also known that carnitine chloride enhances the permeation barrier strength of the epidermis (Japanese Patent Laid-Open No. Hei 5). 11-302143), as in the present invention, has never been shown to promote the production of ceramides in the epidermis by using in combination with one or more fatty acids.
[0009]
In the present invention, one or more of L-carnitine, DL-carnitine and their salts and derivatives are selected and used. These salts include hydrochlorides, acetates, sulfates, etc., and derivatives include various esters such as alkyl esters, alkenyl esters, glyceryl esters, and amides. In the epidermis ceramide production promoter according to the present invention, it is appropriate to contain about 0.0001 to 5.0% by weight in a carrier or the like.
[0010]
The epidermis ceramide production promoter according to the present invention is one or more selected from the above fatty acids and salts and derivatives thereof, and one or two selected from L-carnitine, DL-carnitine and salts and derivatives thereof. The above is solubilized or dispersed in an aqueous carrier such as water, physiological saline or phosphate buffered saline, or a base for external preparations such as a lotion base, emulsion, gel, cream base or ointment base. Can be prepared. Further, it may be encapsulated in microcapsules or liposomes. In addition, a surfactant, an antioxidant, a fungicide, an antifungal agent and the like can be added to the epidermis ceramide production promoter according to the present invention in order to stabilize the preparation.
[0011]
Furthermore, in this invention, 1 type, or 2 or more types of the said skin ceramide production | generation promoter can be used as it is or it is made to contain in various bases, and it can be set as a skin moisturizing function improving agent. A moisturizing agent, skin cell activator, antioxidant, antibacterial and antifungal agent, fragrance and the like can be further added to the skin moisturizing function improving agent.
[0012]
【Example】
Further, the features of the present invention will be described in detail with reference to examples.
[0013]
[Example 1] Epidermal ceramide production promoter 1
(1) Arachidonic acid 0.152g
(2) L-carnitine 1.622g
(3) Soy lecithin 1.000 g
(4) Purified water Mass production method with a total volume of 1.0 liter: Add (1) to (3) to (4) in order and mix and solubilize. . In this example, the arachidonic acid concentration is 5.0 × 10 −4 M, and the L-carnitine concentration is 0.01M.
[0014]
About said Example 1, the ceramide production | generation promotion effect of the epidermis was evaluated. At that time, the same preparation without adding arachidonic acid in Example 1 was made as Comparative Example 1, and the same preparation with double addition of arachidonic acid without addition of L-carnitine was made as Comparative Example 2 at the same time. Evaluation was performed.
[0015]
The ceramide production promoting action of the epidermis was evaluated as follows using normal human epidermal keratinocytes. First, normal human epidermal keratinocytes were seeded at a density of 5,000 cells / dish in a 35 mm diameter dish, and 90% confluent at 37 ° C. in a serum-free liquid medium for proliferation of normal human epidermal keratinocytes (Kurabo). Incubate until reached. Next, 1.0 ml of each of the above Examples and Comparative Examples was added to the medium, and a medium for cell differentiation prepared with a total volume of 100 ml (10 vol% fetal calf serum, 10 μg / ml insulin, 0.4 μg / ml hydrocortisone was added) Dulbecco's modified basal medium (manufactured by Nikken Biomedical Research Institute) and Ham's F-12 medium (manufactured by Kyokuto Pharmaceutical Co., Ltd.), and the culture is performed while changing the medium every two days. Then, lipids were extracted from the keratinocytes recovered from the dish on the 10th day with a chloroform / methanol mixed solvent (volume ratio = 2: 1). The extracted lipid was dried and dissolved in 200 μl of the mixed solvent, and ceramide was quantified by thin layer chromatography. In addition, the system which did not add an Example and a comparative example but changed the culture medium similarly in the culture medium for cell differentiation was made into the control | contrast. The experiment was performed twice for each system, and the average value was calculated and shown in Table 1.
[0016]
[Table 1]
[0017]
As is clear from Table 1, in the system to which Example 1 of the present invention was added, the ceramide content was significantly increased as compared with the control, and promotion of ceramide formation was recognized. In contrast, in the system to which Comparative Example 1 containing only L-carnitine was added, no increase in ceramide content was observed compared to the control, and in the system to which Comparative Example 2 containing only double amounts of arachidonic acid was added. Only a slight increase in the ceramide content was observed, and it was shown that only the fatty acid or L-carnitine cannot provide an effective ceramide production promoting effect.
[0018]
Subsequently, other examples of the epidermis ceramide production promoter according to the present invention will be shown.
[0019]
[Example 2] Epidermal ceramide production promoter 2 (lotion type)
(1) Ethanol 10.00g
(2) Polyoxyethylene (60E.O.) hydrogenated castor oil 0.50g
(3) 0.05 g of isostearic acid
(4) L-carnitine hydrochloride 0.20g
(5) Methyl paraoxybenzoate 0.10 g
(6) Purified water Mass production method with a total volume of 100 ml: (1) to (5) are sequentially added to (6) and dissolved uniformly, and then the total volume is 100 ml.
[0020]
[Example 3] Epidermal ceramide formation promoter 3 (emulsion type)
(1) Stearic acid 0.20 (wt%)
(2) Cetanol 1.50
(3) Petrolatum 3.00
(4) Liquid paraffin 7.00
(5) Polyoxyethylene (10E.O.) monooleic acid 1.50
Ester (6) Tocopherol acetate 0.50
(7) Glycerin 5.00
(8) Methyl paraoxybenzoate 0.10
(9) Potassium hydroxide 0.02
(10) DL-carnitine 0.50
(11) Purified water 80.68
Production method: The oil phase components (1) to (6) are mixed and heated to dissolve uniformly to 70 ° C. On the other hand, the aqueous phase components (7) to (11) are mixed and heated to be uniform, and set to 70 ° C. The oil phase component is gradually added to the aqueous phase component with stirring, emulsified, and cooled.
[0021]
[Example 4] Epidermal ceramide production promoter 4 (gel formulation)
(1) Propylene glycol monostearate 0.02 (wt%)
(2) Dipropylene glycol 10.00
(3) Carboxyvinyl polymer 0.50
(4) Potassium hydroxide 0.10
(5) Methyl paraoxybenzoate 0.10
(6) Purified water 88.93
(7) L-carnitine hydrochloride 0.35
Manufacturing method: (3) is uniformly dissolved in (6), then (1) and (5) are dissolved and added to (2), then (4) is added to increase the viscosity, and (7) is added , Dissolve.
[0022]
[Example 5] Epidermal ceramide production promoter 5 (cream type)
(1) Beeswaw 6.0 (wt%)
(2) Cetanol 5.0
(3) Reduced lanolin 8.0
(4) Squalane 27.5
(5) 9-undecylenic acid, 10-undecylenic acid mixture 0.1
(6) Glyceryl monostearate 2.5
(7) Polyoxyethylene (20E.O.) sorbitan 5.0
Monolaurate (8) Propylene glycol 5.0
(9) Methyl paraoxybenzoate 0.1
(10) L-carnitine acetate 0.5
(11) Purified water 40.3
Production method: The oil phase components (1) to (7) are mixed and dissolved to 75 ° C. On the other hand, the water phase components (8) to (11) are mixed and dissolved and heated to 75 ° C. Next, the oil phase component is added to the aqueous phase component and pre-emulsified, and then uniformly emulsified with a homomixer and cooled.
[0023]
[Example 6] Epidermal ceramide formation promoter 6 (ointment type)
(1) White petrolatum 25.00 (wt%)
(2) Stearyl alcohol 25.00
(3) Palmitic acid 0.01
(4) Behenic acid 0.01
(5) Glycerin 12.00
(6) Sodium lauryl sulfate 1.00
(7) Methyl paraoxybenzoate 0.10
(8) Purified water 36.58
(9) L-carnitine 0.15
(10) DL-carnitine hydrochloride 0.15
Production method: The oil phase components (1) to (6) are mixed and heated to dissolve uniformly to 75 ° C. On the other hand, the water phase components (7) and (8) are mixed and heated to be uniform, and the temperature is set to 75 ° C. The oil phase component is gradually added to the aqueous phase component while stirring to emulsify, and after cooling, (9) and (10) are added and dissolved at 40 ° C.
[0024]
[Example 7] Epidermal ceramide production promoter 7 (liposome)
(1) Soy lecithin 80.00 (g)
(2) Isopalmitic acid 0.05
(3) Linolenic acid 0.02
(4) Tocopherol acetate 0.50
(5) L-carnitine 0.50
(6) Purified water 100.00
Manufacturing method: Add (5) to (6) and dissolve. To this, (2) to (4) are added to (1), mixed and added, suspended at 65 ° C. and then sonicated to prepare liposomes, which are collected by centrifugation.
[0025]
[Example 8] Epidermal ceramide production promoter 8 (microcapsule)
(1) Olive oil 10.0 (% by weight)
(2) Octyldodecyl myristate 0.2
(3) Sodium alginate 0.6
(4) Polyvinyl alcohol 12.0
(5) Glycerin 12.0
(6) L-carnitine 0.2
(7) Purified water 65.0
Production method: (2) is mixed and dissolved in (1), and (3) to (6) are added to (7) and dissolved in the dissolved aqueous solution with stirring. The dispersion is dropped into a 20% by weight calcium chloride aqueous solution while stirring, and the resulting microcapsules are collected by centrifugation.
[0026]
Next, the Example about the skin moisturizing function improving agent which concerns on this invention is shown.
[0027]
[Example 9] Skin moisturizing function improving agent 1
(1) Liquid paraffin 10.0 (% by weight)
(2) White petrolatum 5.0
(3) Cetanol 6.0
(4) Polyoxyethylene (30E.O.) cetyl ether 2.0
(5) Self-emulsifying glyceryl monostearic acid 10.0
Ester (6) Propylene glycol 10.0
(7) Methyl paraoxybenzoate 0.1
(8) Skin ceramide production promoter 1 2.0
(9) Purified water 54.9
Production method: The oil phase components (1) to (5) are mixed and dissolved by heating to 75 ° C. On the other hand, the aqueous phase components (6) to (9) are mixed, dissolved by heating to 75 ° C., and the oil phase is gradually added to this while stirring, then emulsified with a homomixer and cooled.
[0028]
[Example 10] Skin moisturizing function improving agent 2
(1) Liquid paraffin 30.0 (wt%)
(2) Microcrystalline wax 2.0
(3) Vaseline 5.0
(4) Diglyceryl dioleate 5.0
(5) Sodium L-glutamate 1.6
(6) L-serine 0.4
(7) Propylene glycol 3.0
(8) Epidermis ceramide production promoter 2 1.0
(9) Methyl paraoxybenzoate 0.1
(10) Purified water 51.8
(11) Fragrance 0.1
Production method: Dissolve (5) and (6) in a part of (10) to 50 ° C, and gradually add to (4) heated to 50 ° C in advance with stirring. This was mixed in advance and uniformly dispersed in (1) to (3) heated and dissolved at 70 ° C. Then, (7) to (9) were dissolved in the remainder of (10) and heated to 70 ° C. Add with stirring and emulsify with homomixer. After cooling, add and mix (11) at 50 ° C.
[0029]
[Example 11] Skin moisturizing function improving agent 3
(1) Glycerin 2.0 (% by weight)
(2) 1,3-butylene glycol 3.0
(3) Polyoxyethylene (25E.O.) oleyl ether 0.2
(4) Ethanol 10.0
(5) Methyl paraoxybenzoate 0.1
(6) Fragrance 0.1
(7) Purified water 74.6
(8) Epidermal ceramide production promoter 7 10.0
Manufacturing method: Dissolve (5) and (6) in (4), add to (7) together with (1) to (3), mix uniformly, add (8) to this and disperse.
[0030]
[Example 12] Skin moisturizing function improving agent 4
(1) Dipropylene glycol 10.0 (% by weight)
(2) Carboxyvinyl polymer 0.5
(3) Potassium hydroxide 0.1
(4) Methyl paraoxybenzoate 0.1
(5) Purified water 86.8
(6) Epidermal ceramide production promoter 8 2.5
Manufacturing method: (2) is uniformly dissolved in (5), (4) is dissolved and added to (1), then (3) is added to increase the viscosity, and (6) is added and dispersed.
[0031]
A use test was conducted on Examples 9 to 12 of the present invention, and the improvement status of the skin moisturizing function was evaluated. In that case, in Example 9 and Example 11, what was prepared similarly without adding a fatty acid about the epidermis ceramide production | generation promoter 1 and the epidermis ceramide production | generation accelerator 7 was used as the comparative example 3 and the comparative example 5, In Example 10 and Example 12, the same preparation was made without adding L-carnitine or a salt thereof to the epidermal ceramide production accelerator 2 and the epidermal ceramide production accelerator 8, and Comparative Examples 4 and 6 At the same time, it was subjected to a use test.
[0032]
In the use test, 20 male and female panelists in their 10's to 60's who exhibit remarkable rough skin symptoms are grouped together, and each of Examples 9 to 12 and Comparative Examples 3 to 6 is blinded to each group. It was used twice a day for 2 weeks, and the skin condition of each paneler was observed before and after the use test was started, and at the same time, the conductance of the skin surface was measured. The skin condition was evaluated according to the evaluation criteria shown in Table 2 and scored. The average value of 20 persons was calculated | required about the measured value of a skin state and skin surface conductance, and it showed in Table 3 by comparing before the use test start and after the use test end.
[0033]
[Table 2]
[0034]
[Table 3]
[0035]
As is apparent from Table 3, the skin condition in the use group of Examples 9 to 12 of the present invention was improved to a substantially good state, and the conductance value on the skin surface indicating the amount of water in the epidermis increased significantly. It was. On the other hand, in the use groups of Comparative Examples 3 to 6, the improvement of the skin condition is insufficient, and an increase in the conductance value of the skin surface is also observed compared to before the start of the use test, but the degree corresponds to each. It was much smaller than the example use group.
[0036]
【The invention's effect】
As described above in detail, according to the present invention, it was possible to obtain an epidermis ceramide production promoter and an epidermis moisturizing function improving agent that can effectively promote the production of ceramide in the epidermis and improve the moisturizing function of the epidermis.

Claims (1)

  1. An epidermis ceramide production promoter comprising arachidonic acid and L-carnitine .
JP2000029319A 2000-02-07 2000-02-07 Epidermis ceramide production promoter and epidermis moisturizing function improving agent containing the same Expired - Fee Related JP4780817B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2000029319A JP4780817B2 (en) 2000-02-07 2000-02-07 Epidermis ceramide production promoter and epidermis moisturizing function improving agent containing the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000029319A JP4780817B2 (en) 2000-02-07 2000-02-07 Epidermis ceramide production promoter and epidermis moisturizing function improving agent containing the same

Publications (2)

Publication Number Publication Date
JP2001220345A JP2001220345A (en) 2001-08-14
JP4780817B2 true JP4780817B2 (en) 2011-09-28

Family

ID=18554598

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000029319A Expired - Fee Related JP4780817B2 (en) 2000-02-07 2000-02-07 Epidermis ceramide production promoter and epidermis moisturizing function improving agent containing the same

Country Status (1)

Country Link
JP (1) JP4780817B2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10129502A1 (en) * 2001-06-19 2003-01-09 Beiersdorf Ag Use of carnitine and / or one or more acyl-carnitines for the production of cosmetic or dermatological preparations to increase ceramide biosynthesis
DE10133200A1 (en) * 2001-07-07 2003-01-23 Beiersdorf Ag Use of topical compositions containing carnitine and its precursors, derivatives or metabolites to, e.g. improve skin condition or to treat or prevent skin disorders, abnormal lipid peroxidation, reduced cell-cell communication or dandruff
ITMI20041603A1 (en) * 2004-08-04 2004-11-04 Vama Farmacosmetica S R L Raw material for cosmetics based on 1-carnitine for the preparation with a moisturizing cosmetic preparation and long-lasting effect obtained with this raw material
CN101583345A (en) * 2006-11-02 2009-11-18 美露香株式会社 Ceramide synthesis accelerators, cosmetic preparation, skin preparation for external use, method of preventing aging, and method of diminishing wrinkle
JP2014221748A (en) * 2013-05-14 2014-11-27 昭和電工株式会社 Epidermis-related factor activator
CN106265123A (en) * 2016-08-22 2017-01-04 欧诗漫生物股份有限公司 A kind of cosmetics cream containing Cer NS & carnosine submicron liposome and preparation method thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS51148042A (en) * 1975-06-14 1976-12-18 Kanebo Ltd Skin toiletry
JPH0459285B2 (en) * 1987-02-04 1992-09-21 Kao Corp
JPH1129457A (en) * 1997-07-04 1999-02-02 Shusuke Hanaoka Skin cosmetic
JPH11180851A (en) * 1997-12-22 1999-07-06 Shusuke Hanaoka Skin cosmetic
DE19806946A1 (en) * 1998-02-19 1999-09-09 Beiersdorf Ag Combination of (acyl) carnitine and retinoid for use in skin care, effective e.g. against light-induced damage and inflammation
DE19806889A1 (en) * 1998-02-19 1999-08-26 Beiersdorf Ag Treatment or prevention of skin aging using acyl carnitine, effective e.g. against light-induced damage, dry skin and inflammation
DE19806890A1 (en) * 1998-02-19 1999-08-26 Beiersdorf Ag Combination of (acyl) carnitine and oxidant for use in skin care, effective e.g. against light-induced damage and inflammation
DE19806947A1 (en) * 1998-02-19 1999-08-26 Beiersdorf Ag Combination of (acyl) carnitine and (hydro)quinone for use in skin care, effective e.g. against light-induced damage and inflammation
JPH11302143A (en) * 1998-02-20 1999-11-02 Kanebo Ltd Enhancer of barrier strength against permeation through skin, and cosmetic
US6149924A (en) * 1998-07-20 2000-11-21 Biomed Research & Technologies, Inc. Composition for enhancing lipid production, barrier function, hydrogen peroxide neutralization, and moisturization of the skin

Also Published As

Publication number Publication date
JP2001220345A (en) 2001-08-14

Similar Documents

Publication Publication Date Title
AU2002334601B9 (en) Anti-irritating rosacea treatment
ES2242237T3 (en) Stabilized ascorbile compositions.
JP3779733B2 (en) Oxadioic acid and related compounds for the treatment of skin conditions
CN1110302C (en) Oxyacid and related compounds for treating skin disease
US4897308A (en) Compositions comprising aqueous dispersions of lipid spheres
AU679413B2 (en) Lipids for epidermal moisturization and repair of barrier function
US5137725A (en) Dispersion of lipidic spherules
DE3336047C2 (en) Topically administrable pharmaceutical composition with the active ingredient diclofenac
US6203802B1 (en) Composition for the cosmetic and/or pharmaceutical treatment of the upper layers of the epidermis by topical application to the skin, and corresponding preparation process
EP1002526B1 (en) Skin whitening composition containing bearberry extract and a reducing agent
US4610868A (en) Lipid matrix carriers for use in drug delivery systems
EP0072462B1 (en) Pharmaceutical preparations
US5951990A (en) Ascorbyl-phosphoryl-cholesterol
US7597899B2 (en) Compositions comprising a combination of a free sphingoid base and ceramide and uses thereof
JP4954423B2 (en) Sustained release pharmaceutical composition for parenteral administration of biologically active hydrophilic compounds
US5571503A (en) Anti-pollution cosmetic composition
US20020041889A1 (en) Enhancing agent for degradation of desmosomes or stratum corneum desquamation
EP0852941B1 (en) Nanodispersion cosmetic composition
JP2595478B2 (en) Cosmetic compositions and uses thereof acts simultaneously on the surface layers and deep layers of the skin
KR900007185B1 (en) Liposome composition
ES2411656T3 (en) Water based management systems
US5104655A (en) Polyunsaturated acids having vasokinetic action and pharmaceutical and cosmetic formulations containing them
EP0780116B1 (en) External skin preparation
AU686414B2 (en) New pharmaceutical preparation for pain management
AU743528B2 (en) Cosmetic compositions

Legal Events

Date Code Title Description
RD05 Notification of revocation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7425

Effective date: 20061128

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100511

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100709

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110705

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110705

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140715

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees